On July 17, WuXi AppTec (02359.HK) fell 3.15% in regular trading, trading at 154.9 HKD/share, with turnover of 5.26 billion HKD.

On the news front, Hong Kong Exchange filings revealed that JPMorgan reduced its long position in WuXi AppTec H-shares from 11.08% to 10.89% as of July 10, signaling institutional trimming. Meanwhile, the Life Sciences Tools & Services sector came under broad selling pressure, with JOINN down 9.37%, Insilico Medicine down 8.65%, WuXi XDC down 7.0%, XtalPi down 5.78%, and WuXi Biologics down 4.12%.

The stock had previously rallied on the back of multiple investment banks raising target prices — Daiwa lifted its target to 190 HKD, Morgan Stanley to 168 HKD, and UBS to 176.5 HKD — while JPMorgan itself had increased holdings by approximately 4.2 million H-shares in early July. The current pullback reflects short-term profit-taking after the recent run-up.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)